Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune-checkpoint inhibitors march on, now in combinations.

Literature DB >> 24714455

Immune-checkpoint inhibitors march on, now in combinations.

Cormac Sheridan.

Abstract

Mesh：

Substances：

Year: 2014 PMID： 24714455 DOI： 10.1038/nbt0414-297

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

7 in total

1. Human iPSC and ESC translation potential debated.

Authors: Jeffrey L Fox
Journal: Nat Biotechnol Date: 2011-05 Impact factor: 54.908

2. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Authors: Xiao-Hong Ma; Sheng-Fu Piao; Souvik Dey; Quentin McAfee; Giorgos Karakousis; Jessie Villanueva; Lori S Hart; Samuel Levi; Janice Hu; Gao Zhang; Rossitza Lazova; Vincent Klump; John M Pawelek; Xiaowei Xu; Wei Xu; Lynn M Schuchter; Michael A Davies; Meenhard Herlyn; Jeffrey Winkler; Constantinos Koumenis; Ravi K Amaravadi
Journal: J Clin Invest Date: 2014-02-24 Impact factor: 14.808

3. Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors: Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245

Review 4. The blockade of immune checkpoints in cancer immunotherapy.

Authors: Drew M Pardoll
Journal: Nat Rev Cancer Date: 2012-03-22 Impact factor: 60.716

5. OX40 ligand shuts down IL-10-producing regulatory T cells.

Authors: Tomoki Ito; Yui-Hsi Wang; Omar Duramad; Shino Hanabuchi; Olivia A Perng; Michel Gilliet; F Xiao-Feng Qin; Yong-Jun Liu
Journal: Proc Natl Acad Sci U S A Date: 2006-08-21 Impact factor: 11.205

6. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Authors: Julien Fourcade; Zhaojun Sun; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; Bratislav Janjic; Ahmad A Tarhini; Hussein A Tawbi; John M Kirkwood; Stergios Moschos; Hong Wang; Philippe Guillaume; Immanuel F Luescher; Arthur Krieg; Ana C Anderson; Vijay K Kuchroo; Hassane M Zarour
Journal: Cancer Res Date: 2013-12-16 Impact factor: 12.701

7. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

7 in total

Immune-checkpoint inhibitors march on, now in combinations.

1. Human iPSC and ESC translation potential debated.

2. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

3. Hepatotoxicity with combination of vemurafenib and ipilimumab.

Review 4. The blockade of immune checkpoints in cancer immunotherapy.

5. OX40 ligand shuts down IL-10-producing regulatory T cells.

6. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

7. Nivolumab plus ipilimumab in advanced melanoma.

1. Intellectual property issues of immune checkpoint inhibitors.

2. Engineered Materials for Cancer Immunotherapy.

3. Big-cap buying bonanza trickles down to small biotech.

4. Immuno-oncology moves beyond PD-1.

5. BMS bets on targeting IL-8 to enhance cancer immunotherapies.

6. First PD-1 inhibitor breezes across finish line.

7. Key drivers of biomedical innovation in cancer drug discovery.